Sanofi confirmed to FirstWord on Friday that Muzammil Mansuri, head of strategy and business development, has decided to retire from the company at the end of November. The drugmaker indicated that Alban de La Sablière, currently head of business development, and Laurent Van Lerberghe, head of strategy, would take on more responsibilities as of December 1.
The retirement of Mansuri comes amid a strategic review at Sanofi, with new CEO Paul Hudson scheduled to deliver a strategy update on December 10. Sanofi stated that Mansuri, who joined the company in 2016 from Gilead Sciences, where he was in charge of R&D strategy and corporate development, "oversaw the latest acquisitions while, at the same time, structuring partnerships and alliances that contributed to the deployment of our strategy and growth."
The French drugmaker said de La Sablière would be adding alliance management, competitive intelligence and Sanofi Ventures to his list of responsibilities, while Van Lerberghe will now also handle portfolio analytics and corporate strategy. The pair will report directly to Hudson.
Meanwhile, people familiar with the matter recently suggested that Sanofi is exploring various options for its consumer health unit, including a potential outright sale. The sources also indicated that an initial public offering of the business could be worth around $30 billion.
To read more Top Story articles, click here.